learn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
Search
forLearn
1 / 1 resultsResearch
5 / 700 results
research Increased Lactate Dehydrogenase Activity Is Dispensable in Squamous Carcinoma Cells of Origin
High lactate dehydrogenase activity is not necessary for the growth of squamous cell carcinoma.
research Defining Metabolic Flexibility in Hair Follicle Stem Cell Induced Squamous Cell Carcinoma
Blocking both main energy pathways can stop hair follicle stem cell-induced skin cancer growth.
research Recent Advances in Drug Development for Hair Loss
New treatments for hair loss show promise with advanced therapies and better targeting.
research High Fat Diet and the Adipocyte to Myofibroblast Transition: Implications for Systemic Sclerosis Cutaneous Fibrosis
A high fat lard diet may protect against skin fibrosis and affect hair growth.
research Next Generation Human Skin Constructs as Advanced Tools for Drug Development
Advanced human skin models improve drug development and could replace animal testing.
Community Join
5 / 85 resultscommunity Pelage Pharmaceuticals Announces Positive Phase 2a Clinical Trial Results for PP405 in Regenerative Hair Loss Therapy
Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.
community New Study: PP405, developed by Pelage Pharmaceuticals, can reactivate dormant hair follicle stem cells and stimulate natural hair growth by 20%
PP405, developed by Pelage Pharmaceuticals, can reactivate dormant hair follicle stem cells and increase hair growth by 20% in eight weeks, unlike minoxidil or finasteride. However, skepticism remains about its effectiveness and availability, with concerns about funding and the timeline for broader access.
community Approve PP405 quickly you coward
Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.
community is there any news about pp405 please
There is no new information on pp405, with data collection expected to finish by the end of 2025. Users are discussing the timeline for data analysis and completion of Pelage Pharmaceuticals' phase 2 study.
community PELAGE PHASE 2 TRIALS FOR PP405 - Volunteers Needed
PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.